OBJECTIVE: To study macular structure and function in patients with Usher syndrome type III (USH3) caused by mutations in the Clarin 1 gene (CLRN1). METHODS: High-resolution macular images were obtained by adaptive optics scanning laser ophthalmoscopy and spectral domain optical coherence tomography in 3 patients with USH3 and were compared with those of age-similar control subjects. Vision function measures included best-corrected visual acuity, kinetic and static perimetry, and full-field electroretinography. Coding regions of the CLRN1 gene were sequenced. RESULTS: CLRN1 mutations were present in all the patients; a 20-year-old man showed compound heterozygous mutations (p.N48K and p.S188X), and 2 unrelated women aged 25 and 32 years had homozygous mutations (p.N48K). Best-corrected visual acuity ranged from 20/16 to 20/40, with scotomas beginning at 3° eccentricity. The inner segment-outer segment junction or the inner segment ellipsoid band was disrupted within 1° to 4° of the fovea, and the foveal inner and outer segment layers were significantly thinner than normal. Cones near the fovea in patients 1 and 2 showed normal spacing, and the preserved region ended abruptly. Retinal pigment epithelial cells were visible in patient 3 where cones were lost. CONCLUSIONS: Cones were observed centrally but not in regions with scotomas, and retinal pigment epithelial cells were visible in regions without cones in patients with CLRN1 mutations. High-resolution measures of retinal structure demonstrate patterns of cone loss associated with CLRN1 mutations. CLINICAL RELEVANCE: These findings provide insight into the effect of CLRN1 mutations on macular cone structure, which has implications for the development of treatments for USH3. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00254605.
OBJECTIVE: To study macular structure and function in patients with Usher syndrome type III (USH3) caused by mutations in the Clarin 1 gene (CLRN1). METHODS: High-resolution macular images were obtained by adaptive optics scanning laser ophthalmoscopy and spectral domain optical coherence tomography in 3 patients with USH3 and were compared with those of age-similar control subjects. Vision function measures included best-corrected visual acuity, kinetic and static perimetry, and full-field electroretinography. Coding regions of the CLRN1 gene were sequenced. RESULTS:CLRN1 mutations were present in all the patients; a 20-year-old man showed compound heterozygous mutations (p.N48K and p.S188X), and 2 unrelated women aged 25 and 32 years had homozygous mutations (p.N48K). Best-corrected visual acuity ranged from 20/16 to 20/40, with scotomas beginning at 3° eccentricity. The inner segment-outer segment junction or the inner segment ellipsoid band was disrupted within 1° to 4° of the fovea, and the foveal inner and outer segment layers were significantly thinner than normal. Cones near the fovea in patients 1 and 2 showed normal spacing, and the preserved region ended abruptly. Retinal pigment epithelial cells were visible in patient 3 where cones were lost. CONCLUSIONS: Cones were observed centrally but not in regions with scotomas, and retinal pigment epithelial cells were visible in regions without cones in patients with CLRN1 mutations. High-resolution measures of retinal structure demonstrate patterns of cone loss associated with CLRN1 mutations. CLINICAL RELEVANCE: These findings provide insight into the effect of CLRN1 mutations on macular cone structure, which has implications for the development of treatments for USH3. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00254605.
Authors: Inga Ebermann; Hendrik P N Scholl; Peter Charbel Issa; Elvir Becirovic; Jürgen Lamprecht; Bernhard Jurklies; José M Millán; Elena Aller; Diana Mitter; Hanno Bolz Journal: Hum Genet Date: 2006-12-15 Impact factor: 4.132
Authors: Katherine E Talcott; Kavitha Ratnam; Sanna M Sundquist; Anna S Lucero; Brandon J Lujan; Weng Tao; Travis C Porco; Austin Roorda; Jacque L Duncan Journal: Invest Ophthalmol Vis Sci Date: 2011-04-06 Impact factor: 4.799
Authors: Jacque L Duncan; Yuhua Zhang; Jarel Gandhi; Chiaki Nakanishi; Mohammad Othman; Kari E H Branham; Anand Swaroop; Austin Roorda Journal: Invest Ophthalmol Vis Sci Date: 2007-07 Impact factor: 4.799
Authors: Patrick J Kelty; John F Payne; Rupal H Trivedi; Jason Kelty; Esther M Bowie; Berdine M Burger Journal: Invest Ophthalmol Vis Sci Date: 2008-06 Impact factor: 4.799
Authors: Alessandro Iannaccone; Stephen B Kritchevsky; Maria Laura Ciccarelli; Salvatore A Tedesco; Claudio Macaluso; William J Kimberling; Grant W Somes Journal: Invest Ophthalmol Vis Sci Date: 2004-03 Impact factor: 4.799
Authors: Shu Feng; Michael J Gale; Jonathan D Fay; Ambar Faridi; Hope E Titus; Anupam K Garg; Keith V Michaels; Laura R Erker; Dawn Peters; Travis B Smith; Mark E Pennesi Journal: Invest Ophthalmol Vis Sci Date: 2015-09 Impact factor: 4.799
Authors: Jasdeep S Gill; Vasileios Theofylaktopoulos; Andreas Mitsios; Sarah Houston; Ahmed M Hagag; Adam M Dubis; Mariya Moosajee Journal: Int J Mol Sci Date: 2022-04-11 Impact factor: 6.208